Lyu Xin, Zhao Chen, Yan Zhi-Min, Hua Hong
Department of Oral Medicine, Peking University School and Hospital of Stomatology, Beijing, People's Republic of China.
Drug Des Devel Ther. 2016 Mar 16;10:1161-71. doi: 10.2147/DDDT.S100795. eCollection 2016.
To systematically review and assess the efficacy, different treatment protocols (formulation, dosage, and duration), and safety of nystatin for treating oral candidiasis.
Four electronic databases were searched for trials published in English till July 1, 2015. Randomized controlled trials comparing nystatin with other antifungal therapies or a placebo were included. Clinical and/or mycological cure was the outcome evaluation. A meta-analysis or descriptive study on the efficacy, treatment protocols, and safety of nystatin was conducted.
The meta-analysis showed that nystatin pastille was significantly superior to placebo in treating denture stomatitis. Nystatin suspension was not superior to fluconazole in treating oral candidiasis in infants, children, or HIV/AIDS patients. The descriptive investigations showed that administration of nystatin suspension and pastilles in combination for 2 weeks might achieve a higher clinical and mycological cure rate, and using the nystatin pastilles alone might have a higher mycological cure rate, when compared with using nystatin suspensions alone. Nystatin pastilles at a dose of 400,000 IU resulted in a significantly higher mycological cure rate than that administrated at a dose of 200,000 IU. Furthermore, treatment with nystatin pastilles for 4 weeks seemed to have better clinical efficacy than treatment for 2 weeks. Descriptive safety assessment showed that poor taste and gastrointestinal adverse reaction are the most common adverse effects of nystatin.
Nystatin pastille was significantly superior to placebo in treating denture stomatitis, while nystatin suspension was not superior to fluconazole in treating oral candidiasis in infants, children, or HIV/AIDS patients. Indirect evidence from a descriptive study demonstrated that administration of nystatin pastille alone or pastille and suspension in combination is more effective than that of suspension alone; prolonged treatment duration for up to 4 weeks can increase the efficacy of nystatin. More well designed and high quality randomized control studies are needed to confirm these findings.
系统评价和评估制霉菌素治疗口腔念珠菌病的疗效、不同治疗方案(剂型、剂量和疗程)及安全性。
检索四个电子数据库,查找截至2015年7月1日发表的英文试验。纳入比较制霉菌素与其他抗真菌疗法或安慰剂的随机对照试验。以临床和/或真菌学治愈作为结局评估指标。对制霉菌素的疗效、治疗方案及安全性进行荟萃分析或描述性研究。
荟萃分析表明,制霉菌素含片在治疗义齿性口炎方面显著优于安慰剂。制霉菌素混悬液在治疗婴儿、儿童或艾滋病毒/艾滋病患者的口腔念珠菌病方面并不优于氟康唑。描述性研究表明,与单独使用制霉菌素混悬液相比,联合使用制霉菌素混悬液和含片2周可能获得更高的临床和真菌学治愈率,单独使用制霉菌素含片可能具有更高的真菌学治愈率。40万国际单位剂量的制霉菌素含片真菌学治愈率显著高于20万国际单位剂量。此外,制霉菌素含片治疗4周似乎比治疗2周具有更好的临床疗效。描述性安全性评估表明,味道不佳和胃肠道不良反应是制霉菌素最常见的不良反应。
制霉菌素含片在治疗义齿性口炎方面显著优于安慰剂,而制霉菌素混悬液在治疗婴儿、儿童或艾滋病毒/艾滋病患者的口腔念珠菌病方面并不优于氟康唑。描述性研究的间接证据表明,单独使用制霉菌素含片或联合使用含片和混悬液比单独使用混悬液更有效;延长治疗疗程至4周可提高制霉菌素的疗效。需要更多设计良好、高质量的随机对照研究来证实这些发现。